Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1869037 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNA4MCHR1ABL1 | |
| SCHEMBL1869038 | 1.00 | CHRNB2 (0.34) | CHRNB2CHRNA4MCHR1ABL1 | |
| SCHEMBL1876161 | 0.82 | ALK (0.37) | — | |
| SCHEMBL1876159 | 0.82 | ALK (0.37) | — | |
| SCHEMBL1876163 | 0.82 | ALK (0.37) | — | |
| SCHEMBL1872473 | 0.76 | ABL1 (0.46) | CHRNB2CHRNA4MCHR1ABL1 | |
| SCHEMBL1872468 | 0.76 | ABL1 (0.46) | CHRNB2CHRNA4MCHR1ABL1 | |
| SCHEMBL1872472 | 0.76 | ABL1 (0.46) | CHRNB2CHRNA4MCHR1ABL1 | |
| SCHEMBL1872751 | 0.76 | GRIA2 (0.46) | — | |
| SCHEMBL1872753 | 0.76 | GRIA2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240051917-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC (US) | 2024-02-15 | — | — | US | disclosed |
| US-20190100491-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2019-04-04 | — | — | US | disclosed |
| US-20170247360-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC. | 2017-08-31 | — | — | US | disclosed |
| US-20160272625-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20140323502-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOGEN MA INC. | 2014-10-30 | — | — | US | disclosed |
| EP-2445883-B1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. | 2012-12-20 | — | — | US | disclosed |
| US-8278457-B2 | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2445883-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | PFIZER INC. | 2011-05-05 | — | — | US | disclosed |
| WO-2010150192-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105533-A1 | Heterocyclic Sulfonamides, Uses and Pharmaceutical Compositions Thereof | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
| US-20240051917-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
| US-20120322823-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
| US-20140323502-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
| US-20160272625-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
| US-20170247360-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
| US-20190100491-A1 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF | STS, SULT2A1, SULT1A1 | CHRNB2 4702/4885CHRNA4 4381/4885MCHR1 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.